|
|
Line 6: |
Line 6: |
| <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2xv7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2xv7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2xv7 RCSB], [http://www.ebi.ac.uk/pdbsum/2xv7 PDBsum]</span></td></tr> | | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2xv7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2xv7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2xv7 RCSB], [http://www.ebi.ac.uk/pdbsum/2xv7 PDBsum]</span></td></tr> |
| </table> | | </table> |
| + | == Function == |
| + | [[http://www.uniprot.org/uniprot/VEGFD_HUMAN VEGFD_HUMAN]] Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.<ref>PMID:21148085</ref> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 22: |
Line 24: |
| </StructureSection> | | </StructureSection> |
| [[Category: Homo sapiens]] | | [[Category: Homo sapiens]] |
- | [[Category: Aho, K.]] | + | [[Category: Aho, K]] |
- | [[Category: Alitalo, K.]] | + | [[Category: Alitalo, K]] |
- | [[Category: Anisimov, A.]] | + | [[Category: Anisimov, A]] |
- | [[Category: Ballmer-Hofer, K.]] | + | [[Category: Ballmer-Hofer, K]] |
- | [[Category: Jeltsch, M.]] | + | [[Category: Jeltsch, M]] |
- | [[Category: Kalkkinen, N.]] | + | [[Category: Kalkkinen, N]] |
- | [[Category: Leppanen, V M.]] | + | [[Category: Leppanen, V M]] |
- | [[Category: Toivanen, P.]] | + | [[Category: Toivanen, P]] |
- | [[Category: Tvorogov, D.]] | + | [[Category: Tvorogov, D]] |
- | [[Category: Yla-Herttuala, S.]] | + | [[Category: Yla-Herttuala, S]] |
| [[Category: Angiogenesis]] | | [[Category: Angiogenesis]] |
| [[Category: Hormone]] | | [[Category: Hormone]] |
| [[Category: Lymphangiogenesis]] | | [[Category: Lymphangiogenesis]] |
| Structural highlights
Function
[VEGFD_HUMAN] Growth factor active in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in the formation of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.[1]
Publication Abstract from PubMed
Vascular endothelial growth factors (VEGFs) and their tyrosine kinase receptors (VEGFR-1-3) are central mediators of angiogenesis and lymphangiogenesis. VEGFR-3 ligands VEGF-C and VEGF-D are produced as precursor proteins with long N- and C-terminal propeptides and show enhanced VEGFR-2 and VEGFR-3 binding upon proteolytic removal of the propeptides. Two different proteolytic cleavage sites have been reported in the VEGF-D N-terminus. We report here the crystal structure of the human VEGF-D Cys117Ala mutant at 2.9 A resolution. Comparison of the VEGF-D and VEGF-C structures shows similar extended N-terminal helices, conserved overall folds and VEGFR-2 interacting residues. Consistent with this, the affinity and the thermodynamic parameters for VEGFR-2 binding are very similar. In comparison with VEGF-C structures, however, the VEGF-D N-terminal helix was extended by two more turns because of a better resolution. Both receptor binding and functional assays of N-terminally truncated VEGF-D polypeptides indicated that the residues between the reported proteolytic cleavage sites are important for VEGF-D binding and activation of VEGFR-3, but not of VEGFR-2. Thus, we define here a VEGFR-2 specific form of VEGF-D that is angiogenic, but not lymphangiogenic. These results provide important new insights into VEGF-D structure and function.
Structural determinants of vascular endothelial growth factor-D - receptor binding and specificity.,Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K, Alitalo K Blood. 2010 Dec 8. PMID:21148085[2]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K, Alitalo K. Structural determinants of vascular endothelial growth factor-D - receptor binding and specificity. Blood. 2010 Dec 8. PMID:21148085 doi:10.1182/blood-2010-08-301549
- ↑ Leppanen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Yla-Herttuala S, Ballmer-Hofer K, Alitalo K. Structural determinants of vascular endothelial growth factor-D - receptor binding and specificity. Blood. 2010 Dec 8. PMID:21148085 doi:10.1182/blood-2010-08-301549
|